





Table of contents ► Message from the Chair of the Governance Board and the Executive Director **p. 2** • Governance / Our funder **p. 4** • 2016 Achievements **p. 6** • How We Work **p. 7** • HIV **p. 9** • Hepatitis C **p. 13** • Tuberculosis **p. 14** • Product Development **p. 17** • Technical Expertise **p. 18** • Financial Statements **p. 20** • Acronyms **p. 32**



medicines
patent
pool

Vision

The vision of the MPP is a world in which people in low- and middle-income countries have rapid access to affordable and appropriate HIV, hepatitis C and tuberculosis treatments.



Mission

Our mission is to increase access and promote innovation in the fields of HIV, hepatitis C and tuberculosis treatment through voluntary licensing and patent pooling. Founded in 2010 by Unitaid, the MPP works with a range of partners – industry, civil society, international organisations, patient groups and governments – to prioritise and license new and existing medicines for low- and middle-income countries.

Message from the Chair of the Governance Board and the Executive Director

W

e are pleased to present our 2016 Annual Report to all stakeholders and supporters. Twenty sixteen was a dynamic year for the Medicines Patent Pool (MPP) and for the access to medicines field. With MPP funder Unitaid's approval for our expansion into hepatitis C and tuberculosis (TB) in late 2015, we made quick headway in these new disease areas. The MPP signed its first sublicensing agreements for a hepatitis C antiviral and our first memorandum of understanding to promote TB drug development in the early part of the year.

The organisation also made strides in ensuring access to MPP-licensed HIV medicines. Our network of generic pharmaceutical companies – 15 licensees strong – distributed 4.7 billion doses of low-cost antiretrovirals as of December 2016 and had moved several MPP-licensed products to registration. With this progress, the patent pooling model as an effective intervention gained ground in public health debates.



Sigrun Møgedal
Chair of the Governance Board, MPP



Greg Perry
Executive Director, MPP

The United Nations General Assembly's Political Declaration on HIV and AIDS, for example, welcomed the "broadening of the scope of [our] work to promote voluntary partnerships to address hepatitis C and TB" in June. The Lancet Commission on Essential Medicines Policies recognised that the MPP model could support widespread availability of medicines on the World Health Organization (WHO)'s Model Lists of Essential Medicines as well. At year's end, the MPP secured support from the Swiss government to explore our approach to tackling access issues for these medicines.

Importantly, last year we had an opportunity to expand our partnerships, drawing in experts and disease organisations as well as private sector and civil society leaders interested in bettering the lives of tuberculosis and hepatitis C patients. Together with our strong relationships in the HIV community, we are confident that we can play a role in international efforts to meet treatment goals in coming years.

Sigrun Møgedal and Greg Perry

Governance

Governance Board



Sigrun Møgedal
Chair



Charles Clift
Vice-Chair



Claudia Chamas
Member



Michel Manon
Member



Bernard Pécoul
Member



Anban Pillay
Member



Brian Tempest
Member



Jayashree Watal
Member



Anna Zakowicz
Member

Our funder, Unitaid

Unitaid founded the Medicines Patent Pool in 2010 and serves as the MPP's sole funder for HIV, hepatitis C and tuberculosis activities.

An innovative financing mechanism, Unitaid is engaged in finding new ways to prevent, treat and diagnose HIV/AIDS, tuberculosis and malaria more quickly, more affordably and more effectively. It takes game-changing ideas and turns them into practical solutions that can help accelerate the end of the three diseases. The MPP serves as an important implementer of Unitaid's objectives through its engagement with a range of stakeholders to license key medicines for generic manufacture.

Since 2010, Unitaid's investments in the MPP have yielded 10.9 times the value of its initial funding through expansion of generic access in countries and subsequent price reductions of licensed products. Savings are projected to reach \$2.3 billion by 2028 for HIV medicines alone.

"The MPP model supports a collaborative approach among producers, universities, laboratories and others and this makes it possible for many countries to have access to medicines at affordable prices."

Celso Amorim, Chair of the Executive Board at Unitaid

"The MPP is a cornerstone of Unitaid's efforts to transform the HIV and hepatitis C market and rapidly scale up treatment in low- and middle-income countries. Unitaid is also working closely with the MPP and other partners to encourage the development of better treatment options for tuberculosis as a global health priority."

Lelio Marmora, Unitaid's Executive Director

Expert Advisory Group



MPP Team Members

Greg Perry
Executive Director

Chan Park
General Counsel

Maica Trabanco
Associate Counsel

Sandeep Juneja
Business Development Director

Aastha Gupta
Business Development Manager

Yao Cheng
Scientific Manager

Esteban Burrone
Head of Policy

Erika Dueñas
Advocacy Officer
Katherine Moore
Head of Communications
Sophie Thievenaz
Communications Officer
Alnaaze Nathoo
Strategy and Operations Manager

Asma Rehan
Operations Officer
Vincent Chauvin
Finance and Resources Manager
Esperanza Suarez
Finance and Administrative Officer
Sophie Naeye
Office Assistant



2016 Achievements

Extended the HIV licence for ViiV Healthcare's dolutegravir to all lower middle-income countries allowing sublicensees to sell in nations that are home to 94% of people living with HIV in the developing world. Announced the first World Health Organization prequalification submissions for generic dolutegravir less than three years after the drug's approval in Europe. Signed sublicensing agreements for AbbVie's lopinavir and ritonavir for Africa.



Signed first round of sublicences to improve access to Bristol-Myers Squibb's hepatitis C treatment daclatasvir in 112 low- and middle-income countries. Announced negotiations with the Egyptian drug manufacturer Pharco Pharmaceuticals for the hepatitis C drug candidate ravidasvir.

Finalised a memorandum of understanding with the Global Alliance for TB Drug Development (TB Alliance) to promote the development of new, faster-acting tuberculosis regimens and ensure their availability in developing countries. Opened negotiations to license sutezolid, a promising investigational treatment for both drug-susceptible and drug-resistant TB.


IMPACT 2010-2016


1 hepatitis C direct-acting antiviral


100+ ongoing pharmaceutical development projects


12 HIV medicines and an HIV technology platform licensed


312 million US dollars saved


12.9 million patient-years and 4.7 billion doses of HIV treatments delivered through MPP's generic partners

Launched MedsPaL, the Medicines Patents and Licences Database, with information on the intellectual property status of priority HIV, hepatitis C and tuberculosis medicines in developing countries. Brokered memoranda of understandings with three national patent offices to augment MedsPaL's content.

Strengthened collaborations with experts, civil society, patient groups and industry in the HIV, hepatitis C and TB fields. Extended MPP's Expert Advisory Group to 11 new members with hepatitis C and tuberculosis expertise. Added four new generic manufacturing partners, broadening the network to include companies from Bangladesh and Germany.



PRODUCTS LICENSED TO THE MPP (2010-2016)

- abacavir (ABC) paediatrics
- atazanavir (ATV)
- cobicistat (COBI)
- daclatasvir (DCV)*
- darunavir (DRV)
- dolutegravir (DTG)
- elvitegravir (EVG)
- emtricitabine (FTC)
- lopinavir (LPV)
- raltegravir (RAL) paediatrics
- ritonavir (RTV or /r)
- solid drug nanoparticle technology**
- tenofovir alafenamide (TAF)
- tenofovir disoproxil fumarate (TDF)

* Hepatitis C ** HIV technology platform

How We Work

